- News Home
17 April 2014 12:48 pm ,
Vol. 344 ,
Officials last week revealed that the U.S. contribution to ITER could cost $3.9 billion by 2034—roughly four times the...
An experimental hepatitis B drug that looked safe in animal trials tragically killed five of 15 patients in 1993. Now,...
Using the two high-quality genomes that exist for Neandertals and Denisovans, researchers find clues to gene activity...
A new report from the Intergovernmental Panel on Climate Change (IPCC) concludes that humanity has done little to slow...
Astronomers have discovered an Earth-sized planet in the habitable zone of a red dwarf—a star cooler than the sun—500...
Three years ago, Jennifer Francis of Rutgers University proposed that a warming Arctic was altering the behavior of the...
- 17 April 2014 12:48 pm , Vol. 344 , #6181
- About Us
Duke Scientist Under Investigation Resigns
19 November 2010 4:35 pm
A Duke University oncologist who had been the focus of a misconduct investigation has resigned from the university. Anil Potti had published papers in prominent journals identifying gene signatures in tumors that could predict how a patient would respond to treatment. But his work came under scrutiny after two biostatisticians at M.D. Anderson Cancer Center in Houston, Texas, spent years trying and failing to replicate it. The case broke wide open this summer when The Cancer Letter discovered that Potti had falsely claimed to have won a Rhodes scholarship. Duke placed Potti on administrative leave soon after.
Separately, the Journal of Clinical Oncology yesterday retracted one of the papers in question, by Potti and co-author Joseph Nevins, a cancer geneticist. “The authors wish to retract this article because they have been unable to reproduce the experiments,” the notice read. Duke said today that it has “initiated a process” to request retraction of another paper by Potti, which appeared in Nature Medicine.
The Duke case has also brought scrutiny to efforts to use tumor gene patterns to predict prognosis or response to treatment. Duke opened clinical trials that relied on Potti’s work even as others were expressing concerns about their accuracy. Those trials have since been halted, but the Institute of Medicine is setting up a panel to study clinical use of these gene signatures. That’s still in the works.